Navigation LinksBiology NewsHealth NewsBiology TechnologyMedicine Technology


We're sorry, that page (http://www.bio-medicine.org/medicine-technology-1/nuvasive-appoints-new-chief-financial-officer-and-announces-additional-management-updates-6053-1/;+health+history;+medical+history.html) was not found.

Search medicine technology 1 nuvasive appoints new chief financial officer and announces additional management updates 6053 1 ;+health+history;+medical+history html at Google

Search medicine technology 1 nuvasive appoints new chief financial officer and announces additional management updates 6053 1 ;+health+history;+medical+history html at Yahoo

Search medicine technology 1 nuvasive appoints new chief financial officer and announces additional management updates 6053 1 ;+health+history;+medical+history html at Msn

Google
 
Breaking Biology News(10 mins):New understanding of how to prevent destruction of a tumor suppressor 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 1Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 4Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 5Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 6Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 7Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 2Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 1Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 2Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 4Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 5
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2
Breaking Medicine Technology:Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults 2TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 1For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 2For Patients With Irritable Bowel Syndrome 28IBS 29 iPhone to the Rescue 47442 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 1Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 5Study shows gay couples want legal rights regardless of marriage 47439 1Study shows gay couples want legal rights regardless of marriage 47439 2